Evidence map›Paper›PMID 36765830›Full record

ReviewCancers2023

Endemic Kaposi's Sarcoma.

Perla El Zeinaty, Céleste Lebbé, Julie Delyon

Abstract readReview
In one paragraph

Review in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed.

  1. Article
  2. Single-cell and spatial transcriptomics reveal mTOR-driven cellular fate of spindle cells and immune evasion in classic Kaposi's sarcoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Cavitated Pulmonary Nodules: Endemic Kaposi's Sarcoma Recurrence or Another Cause?American journal of respiratory and critical care medicine · 2025
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Perla El ZeinatyDepartment of Dermato-Oncology, AP-HP Hôpital Saint-Louis, F-75010 Paris, France.ORCID 0000-0002-9477-7392
Céleste LebbéDepartment of Dermato-Oncology, AP-HP Hôpital Saint-Louis, F-75010 Paris, France.
Julie DelyonDepartment of Dermato-Oncology, AP-HP Hôpital Saint-Louis, F-75010 Paris, France.ORCID 0000-0002-4557-3377

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Kaposi's sarcoma (KS) is a common neoplasm in Eastern and central Africa reflecting the spread of

Indexed as

endemic Kaposi sarcomaHHV-8Kaposi sarcomaKaposi’s sarcomaKSHV

Identifiers

PMID36765830
PMCPMC9913747

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.